ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/09/24
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic InflammationGlobeNewsWire • 08/07/24
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older AdultsGlobeNewsWire • 07/29/24
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100GlobeNewsWire • 07/25/24
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal ModelGlobeNewsWire • 07/18/24
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/15/24
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International ConventionGlobeNewsWire • 05/14/24
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's DiseaseGlobeNewsWire • 04/29/24
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesGlobeNewsWire • 04/04/24
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/25/24
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney DiseaseGlobeNewsWire • 03/18/24
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024GlobeNewsWire • 03/14/24
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat ObesityGlobeNewsWire • 02/29/24
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsGlobeNewsWire • 02/28/24
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic OptionGlobeNewsWire • 02/22/24
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological DiseasesGlobeNewsWire • 02/14/24
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key MilestonesGlobeNewsWire • 02/07/24
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 DiabetesGlobeNewsWire • 01/31/24
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's DiseaseGlobeNewsWire • 01/24/24
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain MetastasisGlobeNewsWire • 01/17/24
ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All AccessGlobeNewsWire • 01/10/24
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital MarketsGlobeNewsWire • 01/04/24